Data Collection to Design and Validate LEOPARD Predictive Models of Delisting in Liver Transplant Candidates

Status: Recruiting
Location: See all (22) locations...
Study Type: Observational
SUMMARY

Objective: The scientific justification of the LEOPARD TVDCS is therefore to collect a large set of data in liver transplantation candidates listed in Europe a) to design and b) to validate LEOPARD 2nd generation AI-based predictive models of mortality/dropout The primary objective is to develop new predictive models of mortality/drop out on the waitlist in patients with decompensated cirrhosis, or other end-stage chronic liver diseases, and in patients listed for Hepato-cellular carcinoma (HCC). Method: Longitudinal multicenter prospective health care data collection cohort study in 2 sets : Training/development set : Prospective health care data collection in 3,000 patients listed in 50 centres across 7 countries and Validation set: Prospective health care data collection in 1,500 subsequent patients listed in the same 50 centres.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Adult \[age 18;70\] patients listed for:

‣ decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology (subset 1) OR

⁃ other chronic end-stage liver diseases requiring LT, to be listed under a MELD-based allocation system (examples: primary biliary cholangitis, primary sclerosing cholangitis etc…) (subset 2) OR

⁃ HCC\* as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis (subset 3). (HCC diagnosed on Barcelona/EASL criteria or histologically proven. HCC meeting or not Milan criteria, as per center practice.)

• Patients registered on national waiting lists under the MELD offering schemes, regardless of extra MELD points and MELD exceptions are affected or not.

• Patient (or trusted person, family member or close relation, if the patient is unable to be informed) who has been informed and did not express opposition to data collection

∙ (\*Of note, enrolment of patients with T1 tumors (1 single tumor \< 2 cm diameter) not amenable to loco-regional therapies because of decompensation, and prioritized under the MELD system, will be allowed in Subset 1.)

Locations
Other Locations
Austria
Universitätsklinik für Allgemeinchirurgie, Klinische Abteilung für Transplantation
RECRUITING
Vienna
Belgium
Department of Gastroenterology and Hepatology Universitair Ziekenhuis Gent
NOT_YET_RECRUITING
Ghent
France
CHU Jean Minjoz Besançon, Department of Hepatology
RECRUITING
Besançon
CHU Trousseau Tours, Department of Hepatology
RECRUITING
Chambray-lès-tours
CHU Beaujon, Department of Hepatology
RECRUITING
Clichy
Hospital Henri Mondor, Department of Hepatology
RECRUITING
Créteil
CHU Dijon, Department of Hepatology
RECRUITING
Dijon
CHRU Huriez Lille, Department of Hepatology
RECRUITING
Lille
CHU Lyon Croix Rousse, Department of Hepatology
NOT_YET_RECRUITING
Lyon
CHU La Timone AP-HM, Department of Hepatology
NOT_YET_RECRUITING
Marseille
CHRU Montpellier Saint Eloi, Department of Hepatology
RECRUITING
Montpellier
CHU L'Archet Nice, Department of Hepatology
RECRUITING
Nice
CHU La Pitié Salpêtrière, Department of Hepatology
RECRUITING
Paris
CHU Bordeaux Haut Levêque, Department of Hepatology
RECRUITING
Pessac
CHU Pontchaillou Rennes, Department of Hepatology
RECRUITING
Rennes
CHRU Strasbourg, Chirurgie Hepato-bilio-pancreatique et transplantation hepatique Department
RECRUITING
Strasbourg
CHU Purpan Toulouse, Department of Hepatology
RECRUITING
Toulouse
CHU Paul Brousse, Department of Hepatology
RECRUITING
Villejuif
Germany
Universitätsklinikum Schleswig - Holstein | UKSH · Transplantation Medicine
RECRUITING
Kiel
Italy
Italian National Transplant Center
NOT_YET_RECRUITING
Rome
Netherlands
Center for Liver Tumors Leiden of the Leiden University Medical Center (LUMC)
NOT_YET_RECRUITING
Leiden
Spain
Servicio de HepatologíaHospital Universitario y Politécnico La Fe
NOT_YET_RECRUITING
Valencia
Contact Information
Primary
Christophe DUVOUX, MD-PHD
christophe.duvoux@aphp.fr
01 49 81 23 25
Backup
Nihel BERREBEH, Project Manager
nihel.berrebeh@aphp.fr
01 40 27 46 20
Time Frame
Start Date: 2025-02-04
Estimated Completion Date: 2029-02-04
Participants
Target number of participants: 4500
Treatments
Subset 1
Decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology
Subset 2
Other chronic end-stage liver diseases requiring LT, to be listed under a MELD-based allocation system (examples: primary biliary cholangitis, primary sclerosing cholangitis etc…)
Subset 3
Hepato-cellular carcinoma as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis
Sponsors
Collaborators: University of Luxembourg, Italian National Transplant Centre (CNT), La Fe University hospital Valencia (HULAFE), European Society for Organ Transplantation (ESOT)-European Liver and Intestine Transplant Association (ELITA)ELITA
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov